This article was originally published on TipRanks.com Ardelyx, Inc.
Tim Chiang now sees a bigger per share value for ARDX’s tenapanor in the IBS-C market.
Ardelyx’s drug tenapanor gets closer to FDA approval; Cantor’s Mara Goldstein weighs in.
Analysts are cautious to sure-fire confident on mover and shakers sending the Street into a frenzy today.
Tenapanor is a viable drug in the treatment of IBS-C, says Cantor’s Mara Goldstein.
On May 12th, Ardelyx Inc (NASDAQ:ARDX) shares plummeted 39%, quite a stark drop. The cause: a disappointing read-out of the first of two …
Ardelyx Inc (NASDAQ:ARDX) investors are having a rough day after the drug maker reported topline results from its T3MPO-1 trial, the first of …
